Type
Business expansion
Country
France
Region
Bassin Parisien; Haute-Normandie; Seine-Maritime
Location of affected unit(s)
Notre-Dame-de-Bondeville
Sector
Manufacturing
Manufacture Of Chemicals And Pharamceuticals
Manufacture Of Basic Pharmaceutical Products And Pharmaceutical Preparations
21.20 - Manufacture of pharmaceutical preparations

100 jobs
Number of planned job creations
Job creation
Announcement Date
17 June 2019
Employment effect (start)
1 July 2019
Foreseen end date
31 January 2021

Description

South African laboratory Aspen has announced the creation of 100 new jobs by 2021 at its Notre-Dame-de-Bondeville plant thanks to a €65 million investment for the production of injectable anesthetic drugs. The new building will produce 48 million units of these drugs that were previously manufactured by its partner AstraZeneca in Sweden and Australia, Aspen said.

Aspen took over this site in 2014 from the British pharmaceutical company GSK, and had already invested nearly €60 million over the 2014-2018 period to modernise it. The site, which currently employs nearly 700 people, is specialised in the production of sterile injectable drugs, but until now has only manufactured products of the anticoagulant family. The factory exports 92% of its ouput.


Sources

Citation

Eurofound (2019), Aspen, Business expansion in France, factsheet number 98059, European Restructuring Monitor. Dublin, https://restructuringeventsprod.azurewebsites.net/restructuring-events/detail/98059.